Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 6, 2011, Pages 559-575

  Schmajuk, Gabriela ^a   Yazdany, Jinoos ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug monitoring; Drug toxicity; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CHLOROQUINE; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALICYLIC ACID DERIVATIVE; THIOPURINE METHYLTRANSFERASE;

ACUTE HEPATITIS; ACUTE LIVER INJURY; ANEMIA; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BLADDER DISEASE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHITIS; CANCER SCREENING; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOPENIA; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ENZYME DEFICIENCY; EYE EXAMINATION; EYE TOXICITY; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE BLOOD LEVEL; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MACROCYTIC ANEMIA; MUSCULOSKELETAL PAIN; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PANCYTOPENIA; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; RETINA MACULOPATHY; RETINAL TOXICITY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THIOPURINE METHYLTRANSFERASE DEFICIENCY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TOXIC MACULOPATHY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; URINE CYTOLOGY; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIRHEUMATIC AGENTS; DATABASES, BIBLIOGRAPHIC; DRUG MONITORING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 79955970717     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.07.010     Document Type: Article

References (175)

1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999, 42:1785-1796. Guidelines for referral and management of systemic lupus erythematosus in adults.
2. Yazdany J., Panopalis P., Gillis J.Z., Schmajuk G., MacLean C.H., Wofsy D., et al. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009, 61:370-377.
3. Khanna D., Arnold E.L., Pencharz J.N., Grossman J.M., Traina S.B., Lal A., et al. Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. Semin Arthritis Rheum 2006, 35:211-237.
4. American College of Rheumatology Starter Set of Quality Indicators. http://www.rheumatology.org/practice/qmc/drug-safety.asp.
5. Kremer J.M., Alarcon G.S., Lightfoot R.W., Willkens R.F., Furst D.E., Williams H.J., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity American College of Rheumatology. Arthritis Rheum 1994, 37:316-328.
6. Chakravarty K., McDonald H., Pullar T., Taggart A., Chalmers R., Oliver S., et al. BSR and BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008, 47:924-925.
7. Tannenbaum H., Bombardier C., Davis P., Russell A.S. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006, 33:140-157. Third Canadian Consensus Conference Group.
8. Lapraik C., Watts R., Bacon P., Carruthers D., Chakravarty K., D'Cruz D., et al. Guidelines and Audit Working Group BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007, 46:1615-1616. BSR; BHPR Standards.
9. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
10. Gaffney K., Scott D.G.I. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheum 1998, 37:824-836.
11. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
12. Espinoza L.R., Jara L.J., Martinez-Osuna P., Silveira L.H., Cuellar M.L., Seleznick M. Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy. Lupus 1993, 2:9-14.
13. Luo J.C., Chang F.Y., Chen T.S., Ng Y.Y., Lin H.C., Lu C.L., et al. Gastric mucosal injury in systemic lupus erythematosus patients receiving pulse methylprednisolone therapy. Br J Clin Pharmacol 2009, 68:252-259.
14. Karsh J., Kimberly R.P., Stahl N.I., Plotz P.H., Decker J.L. Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus. Arthritis Rheum 1980, 23:1401-1404.
15. Kimberly R.P., Plotz P.H. Aspirin-induced depression of renal function. N Engl J Med 1977, 296:418-424.
16. Horizon A.A., Wallace D.J. Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Exp Opin Drug Saf 2004, 3:273-278.
17. ter Borg E.J., de Jong P.E., Meijer S., Kallenberg C.G. Renal effects of indomethacin in patients with systemic lupus erythematosus. Nephron 1989, 53:238-243.
18. Wolfe F., Michaud K., Li T., Katz R.S. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol 2010, 37(2):305-315.
19. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008, 59(8):1058-1073. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs.
20. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. Ann Intern Med 1994, 121:289-300.
21. White W.B. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007, 49(3):408-418.
22. Pope J., Jerome D., Fenlon D., Krizova A., Ouimet J. Frequency of adverse drug reactions in patients with systemic lupus erythematosus. J Rheumatol 2003, 30:480-484.
23. Lander S.A., Wallace D.J., Weisman M.H. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002, 11:340-347.
24. Seaman W.E., Ishak K.G., Plotz P.H. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 1974, 80:1-8.
25. Travers R., Hughes G.R. Salicylate hepatotoxicity in systemic lupus erythematosus: a common occurrence. BMJ 1978, 2:1532-1533.
26. Schneider V., Levesque L.E., Zhang B., Hutchinson T., Brophy J.M. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006, 164:881-889.
27. Furst D.E., Anderson W. Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1993, 36:804-810.
28. Garcia Rodriguez L.A., Williams R., Derby L.E., Dean A.D., Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994, 154:311-316.
29. Abraham P.A., Keane W.F. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984, 4:1.
30. Panopalis P., Yazdany J. Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009, 11:177-184.
31. Expert Committee on the Diagnosis and Classification of Diabetes. Diabetes Care 1997, 20:1183-1197. 2003;26:3160-7.
32. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327.
33. Andersson DK, Lundblad E, Svardsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabet Med 199;10:167-73.
34. Barile-Fabris L., Ariza-Andraca R., Olguín-Ortega L., Jara L.J., Fraga-Mouret A., Miranda-Limón J.M., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:620-625.
35. Mok C.C., Ying K.Y., Lau C.S., Yim C.W., Ng W.L., Wong W.S., et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004, 43:269-276.
36. Calguneri M., Ozbalkan Z., Ozturk M.A., Apras S., Ertenli A.I., Kiraz S. Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol 2006, 25:782-788.
37. Curtis J.R., Westfall A.O., Allison J., Bijlsma J.W., Freeman A., George V., et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006, 55:420-426.
38. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994, 154:97-101.
39. Chan J.C.N., Cockram C.S., Critchley J.A.J.H. Drug-induced disorders of glucose metabolism: mechanisms and management. Drug Saf 1996, 15:135-157.
40. Braithwaite S.S., Barr W.G., Rahman A., Quddusi S. Managing diabetes during glucocorticoid therapy: how to avoid metabolic emergencies. Postgrad Med 1998, 104:163-166. 171, 175-7.
41. Bootsma H., Spronk P., Derksen R., de Boer G., Wolters-Dicke H., Hermans J., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345:1595-1599.
42. Dammacco F., Della Casa Alberighi O., Ferraccioli G., Racanelli V., Casatta L., Bartoli E. Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 2000, 30:67-73.
43. Panoulas V.F., Douglas K.M., Stavropoulos-Kalinoglou A., Metsios G.S., Nightingale P., Kita M.D., et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:72-75.
44. Whitworth J.A. Mechanism of glucocorticold-induced hypertension. Kidney Int 1987, 31:1213-1224.
45. Mantero F., Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 1992, 43:409-413.
46. Applied Therapeutics: The Clinical Use of Drugs 1992, Applied Therapeutics, Inc, Vancouver (WA). 5th ed. M.A. Koda-Kimble, L.L. Young (Eds.).
47. Illei G.G., Austin H.A., Crane M., Collins L., Gourley M.F., Yarboro C.H., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
48. Chan T.M., Tse K.C., Tang C.S., Mok M.Y., Li F.K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005, 16:1076-1084. Hong Kong Nephrology Study Group.
49. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51-60.
50. Doria A., Shoenfeld Y., Wu R., Gambari P.F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071-1077.
51. Rho Y.H., Oeser A., Chung C.P., Morrow J.D., Stein C.M. Drugs to treat systemic lupus erythematosus: relationship between current use and cardiovascular risk factors. Arch Drug Info 2007, 1:23-28.
52. Bultink I.E., Turkstra F., Diamant M., Dijkmans B.A., Voskuyl A.E. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008, 26:32-38.
53. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
54. Matsumoto T., Yamasaki S., Arakawa A., Abe K., Abe H., Kon K., et al. Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. Pathol Int 2007, 57:388-389.
55. Ettinger W.H., Goldberg A.P., Applebaum-Bowden D., Hazzard W.R. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987, 83:503-508.
56. Ettinger W.H., Hazzard W.R. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988, 37:1055-1105.
57. Brotman D.J., Girod J.P., Garcia M.J., Patel J.V., Gupta M., Posch A., et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005, 90:3202-3208.
58. Taskinen M.R., Kuusi T., Yki-Jarvinen H., Nikkila E.A. Short-term effects of prednisone on serum lipids and high density lipoprotein subfractions in normolipidemic healthy men. J Clin Endocrinol Metab 1988, 67:291-299.
59. Zimmerman J., Fainaru M., Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984, 33:521-526.
60. Svenson K.L., Lithell H., Hallgren R., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987, 147:1917-1920.
61. Choi H.K., Seeger J.D. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 53:528-535.
62. Fraenkel L., Felson D.T. Rheumatologists' attitudes toward routine screening for hydroxychloroquine retinopathy. J Rheumatol 2001, 28:1218-1221.
63. Tehrani R., Ostrowski R.A., Hariman R., Jay W.M. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 2008, 23:201-209.
64. Mavrikakis I., Sfikakis P.P., Mavrikakis E., Rougas K., Nikolaou A., Kostopoulos C., et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003, 110:1321-1326.
65. Wang C., Fortin P.R., Li Y., Panaritis T., Gans M., Esdaile J.M. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol 1999, 26:808-815.
66. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
67. Pluenneke A.C., Blomquist P.H. Utility of red amsler grid screening in a rheumatology clinic. J Rheumatol 2004, 31:1754-1755.
68. Sontheimer R.D. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. Arch Dermatol 2000, 136:1044-1049.
69. Chernof D., Taylor K.S. Hydroxychloroquine-induced agranulocytosis. Arch Dermatol 1968, 97:163-164.
70. Nkhoma E.T., Poole C., Vannappagari V., Hall S.A., Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis 2009, 42(3):267-278.
71. Cappellini M.D., Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008, 371(9606):64-74.
72. Landewé R.B., Vergouwen M.S., Goeei The S.G., Van Rijthoven A.W., Breedveld F.C., Dijkmans B.A. Antimalarial drug induced decrease in creatinine clearance. J Rheumatol 1995, 22:34-37.
73. Giner Galvañ V., Oltra M.R., Rueda D., Esteban M.J., Redón J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 2007, 26:971-972.
74. Makin A.J., Wendon J., Fitt S., Portmann B.C., Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994, 35:569-570.
75. Moroni G., Doria A., Mosca M., Alberighi O.D., Ferraccioli G., Todesco S., et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006, 1:925-932.
76. Contreras G., Tozman E., Nahar N., Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005, 14(Suppl 1):s33-s38.
77. Decker J.L., Klippel J.H., Plotz P.H., Steinberg A.D. Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. Ann Intern Med 1975, 83:606-615.
78. Jun J.B., Cho D.Y., Kang C., Bae S.C. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005, 23:873-876.
79. Naughton M.A., Battaglia E., O'Brien S., Walport M.J., Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999, 38:640-644.
80. Connell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081-1085.
81. Winter J.W., Gaffney D., Shapiro D., Spooner R.J., Marinaki A.M., Sanderson J.D., et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007, 25:1069-1077.
82. Huskisson E.C. Azathioprine. Clin Rheum Dis 1984, 10:325.
83. Whisnant J.K., Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN R). Clinical side effects and laboratory abnormalities. Ann Rheum Dis 1982, 41(Suppl 1):44-47.
84. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651.
85. Gearry R.B., Day A.S., Barclay M.L., Leong R.W., Sparrow M.P. Azathioprine and allopurinol: a two-edged interaction. J Gastroenterol Hepatol 2010, 25(4):653-655.
86. Drug information 2007, Azathioprine, Lexi-Comp.
87. Grootscholten C., Ligtenberg G., Hagen E.C., van den Wall Bake A.W., de Glas-Vos J.W., Bijl M., et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006, 70:732-742.
88. Yee C.S., Gordon C., Dostal C., Petera P., Dadoniene J., Griffiths B., et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004, 63:525-529.
89. Contreras G., Pardo V., Leclercq B., Lenz O., Tozman E., O'Nan P., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980.
90. DePinho R.A., Goldberg C.S., Lefkowitch J.H. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984, 86:162-165.
91. Praprotnik S., Hocevar A., Ferlan-Marolt V., Tomsic M. Azathioprine induced hepatic veno-occlusive disease in systemic lupus erythematosus. Lupus 2005, 14:493-494.
92. Askanase A.D., Wallace D.J., Weisman M.H., Tseng C.E., Bernstein L., Belmont H.M., et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:89-95.
93. de Boer N.K., van Bodegraven A.A., Jharap B., de Graaf P., Mulder C.J. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007, 4:686-694.
94. Romagnuolo J., Sadowski D.C., Lalor E., Jewell L., Thomson A.B. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998, 12:479-483.
95. McLeod H.L., Lin J.S., Scott E.P., Pui C.H., Evans W.E. Thiopurine methyltransferase activity in white subjects and black subjects. Clin Pharmacol Ther 1994, 55:15-20.
96. Evans W.E. Comprehensive assessment of thiopurine S-methyltransferase alleles in three ethnic populations. J Pediatr Hematol Oncol 2002, 24:335-336.
97. McLeod H.L., Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002, 3:89-98.
98. Schedel J., Godde A., Schutz E., Bongartz T.A., Lang B., Scholmerich J., et al. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann NY Acad Sci 2006, 1069:477-491.
99. Decaux G., Horsmans Y., Houssiau F., Desager J.P. High 6-thioguanine nucleotide levels and low thiopurine methyltransferase activity in patients with lupus erythematosus treated with azathioprine. Am J Ther 2001, 8:147-150.
100. Klemetsdal B., Wist E., Aarbakke J. Gender difference in red blood cell thiopurine methyltransferase activity. Scand J Clin Lab Invest 1993, 53:747-749.
101. Pazmino P.A., Sladek S.L., Weinshiboum R.M. Thio S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmcol Ther 1980, 28:356-367.
102. Okada Y., Nakamura K., Kodama T., Ueki K., Tsukada Y., Maezawa A., et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharm Bull 2005, 28:2117-2119.
103. Black A.J., McLeod H.L., Capell H.A., Powrie R.H., Matowe L.K., Pritchard S.C., et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998, 129:716-718.
104. Ong L.M., Hooi L.S., Lim T.O., Goh B.L., Ahmad G., Ghazalli R., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005, 10:504-510.
105. Wang J., Hu W., Xie H., Zhang H., Chen H., Zeng C., et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007, 16:707-712.
106. Traitanon O., Avihingsanon Y., Kittikovit V., Townamchai N., Kanjanabuch T., Praditpornsilpa K., et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 2008, 17:744-751.
107. Austin H.A., Illei G.G., Braun M.J., Balow J.E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009, 20:901-911.
108. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112.
109. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
110. Cortés-Hernández J., Ordi-Ros J., Labrador M., Segarra A., Tovar J.L., Balada E., et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003, 12:287-296.
111. Donadio J.V., Holley K.E., Ferguson R.H., Ilstrup D.M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978, 299:1151-1155.
112. Mok C.C., Ying K.Y., Ng W.L., Lee K.W., To C.H., Lau C.S., et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006, 119:355.e25-355.e33.
113. Katsifis G.E., Tzioufas A.G., Vlachoyiannopoulos P.G., Voulgarelis M., Moutsopoulos H.M., Ioannidis J.P. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41:780-786.
114. Drug Information 2007, Cyclophosphamide, Lexi-Comp.
115. Plotz P.H., Klippel J.H., Decker J.L., Grauman D., Wolff B., Brown B.C., et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979, 91:221-223.
116. Austin H.A., Klippel J.H., Balow J.E., le Riche N.G., Steinberg A.D., Plotz P.H., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs N Engl J Med 1986, 314:614-619.
117. Martin-Suarez I., D'Cruz D., Mansoor M., Fernandes A.P., Khamashta M.A., Hughes G.R. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
118. Monach P.A., Arnold L.M., Merkel P.A. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010, 62:9-21.
119. Herr H.W., Shipley W.U., Bajorin D.F. Cancer of the bladder. Cancer: Principles and Practice of Oncology 2001, 1396-1418. Lippincott, Williams & Wilkins, Philadelphia (PA). 6th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
120. Landman J., Chang Y., Kavaler E., Droller M.J., Liu B.C. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998, 52:398-402.
121. Knight A., Askling J., Granath F., Sparen P., Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004, 63:1307-1311.
122. Talar-Williams C., Hijazi Y.M., Walther M.M., Linehan W.M., Hallahan C.W., Lubensky I., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477-484.
123. Bacon A.M., Rosenberg S.A. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982, 97:62-63.
124. Goldberg J.W., Lidsky M.D. Cyclophosphamide-associated hepatotoxicity. South Med J 1985, 78:222-223.
125. Muratori L., Ferrari R., Muratori P., Granito A., Bianchi F.B. Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis. Dig Dis Sci 2005, 50:2364-2365.
126. Gourley M.F., Austin H.A., Scott D., Yarboro C.H., Vaughan E.M., Muir J., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996, 125:549-557.
127. Gayed M., Bernatsky S., Ramsey-Goldman R., Clarke A., Gordon C. Lupus and cancer. Lupus 2009, 18:479-485.
128. Blumenfeld Z., Lorber M., Yoffe N., Scharf Y. Systemic lupus erythematosus: predisposition for uterine cervical dysplasia. Lupus 1994, 3:59-61.
129. Ognenovski V.M., Marder W., Somers E.C., Johnston C.M., Farrehi J.G., Selvaggi S.M., et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004, 31:1763-1767.
130. Nyberg G., Eriksson O., Westberg N. Increased evidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. Arthritis Rheum 1981, 24:648-650.
131. Carneiro J.R.M., Sato E.I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999, 26:1275-1279.
132. Gansauge S., Breitbart A., Rinaldi N., Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997, 56:382-385.
133. Wilson K., Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994, 21:1674-1677.
134. Wong J.M., Esdaile J.M. Methotrexate in systemic lupus erythematosus. Lupus 2005, 14:101-105.
135. Sato E.I. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001, 10:162-164.
136. Rahman P., Humphrey-Murto S., Gladman D.D., Urowitz M.B. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998, 25:243-246.
137. Suarez-Almazor M.E., Belseck E., Shea B., Wells G., Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000, CD000957.
138. Kremer J.M., Lee R.G., Tolman K.G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989, 32:121-127.
139. Kremer J.M., Kaye G.I., Kaye N.W., Ishak K.G., Axiotis C.A. Light and electron microscopic analysis of sequential liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Follow up over long treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995, 38:1194-1203.
140. Kremer J.M., Furst D.E., Weinblatt M.E., Blotner S.D. Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996, 23:459-461.
141. Kremer J.M., Phelps C.T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum 1992, 35:138-145.
142. Furst D.E., Erikson N., Clute L., Koehnke R., Burmeister L.F., Kohler J.A. Adverse experience with methotrexate during 176 weeks of a long term prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990, 17:1628-1635.
143. Weinblatt M.E., Weissman B.N., Holdsworth D.E., Fraser P.A., Maier A.L., Falchuk K.R., et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992, 35:129-137.
144. Fortin P.R., Abrahamowicz M., Ferland D., Lacaille D., Smith C.D., Zummer M., et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008, 59:1796-1804.
145. Weinblatt M.E., Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989, 32:1592-1596.
146. Gutierrez-Urena S., Molina J.F., Garcia C.O., Cuellar M.L., Espinoza L.R. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996, 39:272-276.
147. Methotrexate, Lexi-Comp Online Lexi-Comp, Inc. Hudson, OH, Accessed June 15, 2008. http://online.lexi.com/crlonline.
148. Izzedine H., Launay-Vacher V., Karie S., Caramella C., de Person F., Deray G. Is low-dose methotrexate nephrotoxic?. Case report and review of the literature. Clin Nephrol 2005, 64:315-319.
149. Basile C., Montnaro A., Semetaro A. Should low dose methotrexate therapy be prescribed to dialysis patients?. Nephrol Dial Transplant 2002, 17:530-531.
150. Yang C.P., Kuo M.C., Guh J.Y., Chen H.C. Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Ren Fail 2006, 28:95-97.
151. Kremer J.M., Alarcón G.S., Weinblatt M.E., Kaymakcian M.V., Macaluso M., Cannon G.W., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40:1829-1837.
152. Howes M., Tose J., White C., Kumar N., Heycock C., Kelly C. Can baseline pulmonary function tests predict pulmonary toxicity in patients receiving methotrexate for rheumatoid arthritis?. Intern Med 1999, 7:51-54.
153. Saravanan V., Kelly C.A. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004, 43(2):143-147.
154. Cottin V., Tébib J., Massonnet B., Souquet P.J., Bernard J.P. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996, 109:933-938.
155. Hagiyama H., Kubota T., Komano Y., Kurosaki M., Watanabe M., Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004, 22:375-376.
156. Ito S., Nakazono K., Murasawa A., Mita Y., Hata K., Saito N., et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001, 44:339-342.
157. Narvaez J., Rodriguez-Moreno J., Martinez-Aguila M.D., Clavaguera M.T. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998, 25:2037-2038.
158. Flowers M.A., Heathcote J., Wanless I.R., Sherman M., Reynolds W.J., Cameron R.G., et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990, 112:381-382.
159. Kujawska A., Clements M., Wise C.M., Roberts W.N. Hepatitis C and methotrexate. Arthritis Rheum 2003, 49:843-845.
160. F L., Y T., X P., L W., H W., Z S., et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008, 17:622-629.
161. Borba E.F., Guedes L.K., Christmann R.B., Figueiredo C.P., Gonçalves C.R., Bonfá E. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 2006, 26:1078-1083.
162. Riskalla M.M., Somers E.C., Fatica R.A., McCune W.J. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003, 30:1508-1512.
163. Pisoni C.N., Sanchez F.J., Karim Y., Cuadrado M.J., D'Cruz D.P., Abbs I.C., et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005, 32:1047-1052.
164. Iaccarino L., Arienti S., Rampudda M., Canova M., Atzeni F., Sarzi Puttini P., et al. Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann NY Acad Sci 2007, 1110:516-524.
165. Bardsley-Elliot A., Noble S., Foster R.H. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. BioDrugs 1999, 12:363-410.
166. Balal M., Demir E., Paydas S., Sertdemir Y., Erken U. Uncommon side effect of MMF in renal transplant recipients. Ren Fail 2005, 27:591-594.
167. Parker G., Bullingham R., Kamm B., Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996, 36:332-344.
168. Sobrin L., Christen W., Foster C.S. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008, 115:1416-1421.
169. Pirmohamed M., Ferner R.E. Monitoring drug treatment. BMJ 2003, 327:1179-1181.
170. Visser K., van der Heijde D.M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009, 27:1017-1025.
171. Platt R., Wilson M., Chan K.A., Benner J.S., Marchibroda J., McClellan M. The new Sentinel Network---improving the evidence of medical-product safety. N Engl J Med 2009, 361:645-647.
172. Smith C.C., Bernstein L.I., Davis R.B., Rind D.M., Shmerling R.H. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003, 163:688-692.
173. Marra C.A., Esdaile J.M., Anis A.H. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002, 29:2507-2512.
174. Oh K.T., Anis A.H., Bae S.C. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004, 43:156-163.
175. Compagni A., Bartoli S., Buehrlen B., Fattore G., Ibarreta D., de Mesa E.G. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care 2008, 24:294-302.